NasdaqCM - Delayed Quote USD

Creative Medical Technology Holdings, Inc. (CELZ)

4.3850 -0.0300 (-0.68%)
At close: June 7 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
9.0000
9.0000
88.6000
87.7540
164.5000
--
Cost of Revenue
3.6000
3.6000
28.4910
47.9490
50.5960
--
Gross Profit
5.4000
5.4000
60.1090
39.8050
113.9040
--
Operating Expense
5,635.6090
5,625.5320
10,304.4810
3,165.7540
1,228.7390
--
Operating Income
-5,630.2090
-5,620.1320
-10,244.3720
-3,125.9490
-1,114.8350
--
Net Non Operating Interest Income Expense
354.0140
333.5580
100.3280
-4,278.4330
-1,229.5900
--
Other Income Expense
--
--
--
26,616.1500
-33,980.8050
-5,457.9770
Pretax Income
-5,276.1950
-5,286.5740
-10,144.0440
19,211.7680
-36,325.2300
--
Net Income Common Stockholders
-5,276.1950
-5,286.5740
-10,144.0440
19,211.7680
-36,325.2300
--
Diluted NI Available to Com Stockholders
-5,276.1950
-5,286.5740
-10,144.0440
19,211.7680
-36,325.2300
--
Basic EPS
-3.74
-3.76
-9.28
184.25
-626.90
--
Diluted EPS
-3.74
-3.76
-9.28
140.25
-626.90
--
Basic Average Shares
1,411.0860
1,407.6320
1,093.2040
104.2020
57.9460
--
Diluted Average Shares
1,411.0860
1,407.6320
1,093.2040
129.9440
57.9460
--
Total Operating Income as Reported
-5,630.2090
-5,620.1320
-10,244.3720
-3,125.9490
-1,114.8350
--
Total Expenses
5,639.2090
5,629.1320
10,332.9720
3,213.7030
1,279.3350
--
Net Income from Continuing & Discontinued Operation
-5,276.1950
-5,286.5740
-10,144.0440
19,211.7680
-36,325.2300
--
Normalized Income
-5,276.1950
-5,286.5740
-10,144.0440
-7,404.3820
-2,344.4250
--
Interest Income
353.9640
333.5580
100.3280
--
--
--
Interest Expense
2,402.7460
--
--
4,278.4330
1,229.5900
1,895.5280
Net Interest Income
354.0140
333.5580
100.3280
-4,278.4330
-1,229.5900
--
EBIT
-5,609.8030
-5,620.1320
-10,244.3720
23,490.2010
-35,095.6400
--
EBITDA
-5,508.9690
-5,525.5480
-10,152.2880
23,582.2850
-35,028.8480
--
Reconciled Cost of Revenue
3.6000
3.6000
28.4910
47.9490
50.5960
--
Reconciled Depreciation
100.8340
94.5840
92.0840
92.0840
66.7920
--
Net Income from Continuing Operation Net Minority Interest
-5,276.1950
-5,286.5740
-10,144.0440
19,211.7680
-36,325.2300
--
Total Unusual Items Excluding Goodwill
--
--
--
26,616.1500
-33,980.8050
-5,457.9770
Total Unusual Items
--
--
--
26,616.1500
-33,980.8050
-5,457.9770
Normalized EBITDA
-5,508.9690
-5,525.5480
-10,152.2880
-3,033.8650
-1,048.0430
--
12/31/2019 - 11/6/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TSOI Therapeutic Solutions International, Inc.
0.0008
-11.11%
 
ENSC Ensysce Biosciences, Inc.
0.5455
+0.06%
 
NRBO NeuroBo Pharmaceuticals, Inc.
3.9300
-1.26%
 
REVB Revelation Biosciences, Inc.
2.2000
-3.08%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.7200
-1.37%
 
PALI Palisade Bio, Inc.
4.5700
-2.56%
 
PBM Psyence Biomedical Ltd.
0.6700
-3.74%
 
USRM U.S. Stem Cell, Inc.
0.0001
0.00%
 
HOTH Hoth Therapeutics, Inc.
1.0900
-6.03%
 
TCBP TC Biopharm (Holdings) Plc
1.0800
-7.69%